Application of trichosanthin agonist TLR7 in enhancing immune protection efficacy of novel coronavirus vaccine

By specifically binding pollen protein to TLR7 protein, it serves as a TLR7 agonist and vaccine adjuvant, solving the side effects of TLR7 agonists and enhancing the immune efficacy of the novel coronavirus vaccine, especially the protective efficacy in non-responders or weak responders.

CN118924890APending Publication Date: 2024-11-12SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410938609.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-14
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing TLR7 agonists, while enhancing humoral immune responses, have systemic side effects, limiting their application in COVID-19 vaccines. Furthermore, some recipients fail to achieve protective antibody titers, resulting in no or weak immune responses.

Method used

By utilizing the specific protein affinity between pollen protein and TLR7 protein, pollen protein can be used as a TLR7 agonist to enhance the immunoprotective efficacy of the novel coronavirus vaccine. Pollen protein is applied by preparing TLR7 agonists and vaccine adjuvants.

Benefits of technology

It significantly enhanced the immunoprotective efficacy of the novel coronavirus vaccine, improved the immune response of recipients, especially non-responders or weak responders, and expanded the scope of individual protection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924890A_ABST
    Figure CN118924890A_ABST
Patent Text Reader

Abstract

According to the application of the trichosanthin in preparation of the novel coronavirus vaccine immunologic adjuvant, the trichosanthin and a TLR7 molecule have inter-protein specific high affinity, and the immunoprotection efficacy of the novel coronavirus vaccine is remarkably enhanced by exciting the TLR7. The traditional Chinese medicine trichosanthin is innovatively applied to the improvement of the immune protection efficacy of the new crown vaccine, the immune response of the organism to the vaccine is enhanced under the condition of using relatively low immunogen, and the protection on individuals is expanded and enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to the use of trichosanthin to stimulate TLR7 in the preparation of a new coronavirus vaccine immune adjuvant. Background Art

[0002] Toll-like receptors (TLRs) are highly conserved and important components of the innate immune system. TLR3, 7, 8, and 9 expressed in intracellular membrane structures can recognize nucleic acids of viruses and bacteria and trigger strong antiviral and antitumor immune responses. TLR7 is located on the endosomal membrane of immune cells and is mainly expressed in pDCs and B cells. It can recognize single-stranded RNA (ssRNA) and send signals through the MyD88-dependent pathway. Among natural ligands, guanosine-rich ORNs activate TLR7- and TLR8-dependent signaling. TLR7 plays a very important role in both antiviral innate immune responses and the induction of adaptive immunity. The TLR7 signaling pathway, CD40 signaling pathway, and BCR signaling pathway on B cells can synergistically promote the differentiation of antibody secreting cells (ASCs) and participate in antibody subtype conversion. At present, more than 15 new heterocyclic molecules have been discovered, such as imidazoquinoline, pterin, pyrimidine, pyridine pyrimidine, pyrrolopyrimidine, and benzimidazole, and have been identified as TLR7 agonists. Among them, imiquimod (R-837) has been approved by the FDA for marketing, and a variety of other TLR7 agonists are in the clinical development stage, mainly for two types of indications: antiviral and tumor immunotherapy. R-837 can treat genital warts caused by human papillomavirus by enhancing antigen presentation and promoting antigen-specific Th1 cell-mediated immune responses. It has been widely used in clinical practice as a therapeutic drug for viral skin diseases and superficial skin tumors. The oral TLR7 agonist GS-9620 (Vesatolimod) has completed the Phase II clinical trial for the treatment of chronic hepatitis B, and the clinical trial for HIV treatment is still in the Phase I clinical stage. TQ-A3334 and SHR2150 are currently in the Phase I clinical stage, mainly for tumor treatment. Therefore, the development and application of TLR7 agonists have broad prospects.

[0003] However, a common disadvantage of TLR7 agonists is reactogenicity. While promoting humoral immunity, they can also cause harmful systemic reactions and have side effects on the human body. The systemic immune-related toxic side effects (such as systemic immune storm) caused by intravenous injection of R-837 have greatly limited the further development and application of its clinical dosage forms. How to exert the immunomodulatory effect of TLR7 agonists without side effects on the body still faces a series of challenges. Trichosanthin (TCS) is isolated from the root of the traditional Chinese medicine Trichosanthes kirilowii. It is a single-chain plant basic protein with a molecular weight of 24kD, an isoelectric point of 9.4, and is composed of 247 amino acids. The protein crystal structure has been elucidated. The preparation and separation of TCS is simple, the price is low, and the clinical application is safe. Studies have shown that trichosanthin has anti-tumor, anti-early pregnancy, and anti-infection effects, but there are no related studies that disclose the use of trichosanthin as a TLR7 agonist in enhancing the immune protection efficacy of the new crown vaccine.

[0004] For the new coronavirus vaccine, after normal people are vaccinated according to the standard regimen and complete an immunization program, 5% to 10% of the vaccine recipients still have antibody titers that cannot reach the protective threshold (i.e. no response or weak response), and they still cannot get immune protection after vaccination, which may make these people susceptible to the new coronavirus. At present, the occurrence of no response and weak response to the new coronavirus vaccine is affected by many factors, and its mechanism is still unclear. In the process of preparing or using vaccines, being able to select suitable adjuvants to help induce a stronger and more lasting immune response is of great significance for the prevention of the new coronavirus. Summary of the invention

[0005] The first object of the present invention is to provide the use of trichosanthin in the preparation of TLR7 agonists. There is a specific protein affinity between trichosanthin and TLR7 protein, and trichosanthin can be used as an effective agonist of TLR7.

[0006] The second purpose of the present invention is to provide the application of trichosanthin in the preparation of new coronavirus vaccine immune adjuvant.

[0007] In order to achieve the above-mentioned purpose, the present invention discloses the use of trichosanthin in the preparation of TLR7 agonist, which is suitable for enhancing TLR7 in preventive and therapeutic vaccines.

[0008] The present invention also discloses the use of trichosanthin in the preparation of a novel coronavirus vaccine immune adjuvant. There is a specific protein affinity between trichosanthin and TLR7 protein, which significantly enhances the immune protection efficacy of the novel coronavirus vaccine by stimulating TLR7.

[0009] As a preferred embodiment, the new coronavirus vaccine includes oral vaccine, intravenous vaccine, arterial vaccine, mucosal vaccine, intramuscular vaccine, subcutaneous vaccine, organ injection vaccine or intrathoracic and intraperitoneal injection vaccine.

[0010] As a preferred embodiment, the new coronavirus vaccine includes but is not limited to the inactivated new coronavirus vaccine CoronaVac and the inactivated new coronavirus vaccine (Vero cells).

[0011] As a preferred technical solution of the present invention, the immune vaccine adjuvant is administered simultaneously with the supporting new coronavirus vaccine.

[0012] As a preferred embodiment, the vaccine immune adjuvant is a component of the new coronavirus vaccine preparation and is administered simultaneously with the vaccine. The immune vaccine adjuvant can also be administered at intervals with the supporting new coronavirus vaccine.

[0013] In the present invention, the trichosanthin can be used simultaneously with the new coronavirus vaccine, or used separately. In the process of simultaneous use, the trichosanthin can function as a component of the vaccine; in the process of separate use, the trichosanthin can be used before or after the new coronavirus vaccine is used, preferably after the injection of the vaccine, and its use includes injection, oral administration, etc. The trichosanthin can improve the immune effect of the new coronavirus vaccine, especially for those who have no response or weak response to the vaccine, and can promote such people to obtain better immune effects.

[0014] The advantage of the present invention is that it provides protein-specific high affinity between trichosanthin and TLR7 molecules, which significantly enhances the immune protection efficacy of the new coronavirus vaccine by stimulating TLR7. The rational use of trichosanthin can better promote the research and development and upgrading of the new coronavirus vaccine, enhance the body's immune response to the new coronavirus vaccine when using the same immunogen, and expand and enhance the protection of individuals. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 :Display of possible binding sites between TCS and mouse TLR7 protein.

[0016] Figure 2 : Co-localization immunofluorescence images of TCS and TLR7 binding in B cells.

[0017] Figure 3 : Detection diagram of affinity between TCS and mouse and human TLR7 proteins.

[0018] Figure 4 : TCS increases the level of antigen-specific antibodies in mice and enhances the expression of TLR7 in B cells.

[0019] Figure 5 :TCS significantly promotes the proliferation of germinal center B cells and plasma cells through the TLR7 signaling pathway. DETAILED DESCRIPTION

[0020] The technology of the present invention is described in detail below in conjunction with specific embodiments. It should be noted that the following specific embodiments are only used to help those skilled in the art understand the present invention, and are not intended to limit the present invention.

[0021] In the following examples, unless otherwise specified, all reagents and consumables used were purchased from conventional reagent manufacturers in the field; unless otherwise specified, all experimental methods and technical means used were conventional methods and means in the field.

[0022] Example 1. TCS has high affinity for TLR7

[0023] Molecular docking autodock predicted that TCS and mouse TLR7 protein have high affinity. In the protein structure database PDB, TCS is numbered 1NLI and mouse TLR7 protein is numbered 5B1 R. ClusPro was used to predict the binding of the two, and PDBePISA was used to analyze that the two have multiple binding sites, and the area of ​​their interaction surface is The energy is -9.2 kcal / mol, such as Figure 1 As shown: TCS and TLR7 have a strong affinity.

[0024] In vitro immunofluorescence colocalization experiments have shown that TCS binds to TLR7 in pan-B cells of mouse spleen. After TCS was co-cultured with pan-B cells sorted from the spleen of WT C57BL / 6J female mice in vitro, immunofluorescence colocalization detection was performed using a fluorescence confocal microscope, such as Figure 2 The results showed that the green fluorescence representing TCS and the red fluorescence representing TLR7 could overlap at the same position of B cells to form yellow fluorescence, suggesting that TCS and TLR7 bind to each other in B cells.

[0025] The Biacore T200 full-function molecular interaction detection system was used to detect and verify whether there was an interaction between TCS and TLR7 using SPR technology. TCS was immobilized on the surface of the CM5 chip as a ligand with a coupling amount of 13896.9RU to detect the binding of mouse and human TLR7 recombinant proteins with different concentrations and TCS. Figure 3As shown, the binding affinity of TCS to mouse TLR7 protein was 92.23 nM, ka (1 / Ms) was 4.884E+4, kd (1 / s) was 0.04504, and KD (M) was 9.223E-7; the binding affinity of TCS to human TLR7 protein was 4.879 μM, ka (1 / Ms) was 4.359E+4, kd (1 / s) was 0.2127, and KD (M) was 4.879E-7, which further confirmed the existence of specific protein affinity between TCS and TLR7 protein.

[0026] Example 2. TCS enhances the immune response of mice to the novel coronavirus vaccine and upregulates TLR7 expression

[0027] Mouse immunization experiments confirmed that TCS can effectively enhance the level of mouse-specific antibodies and maintain it for a long time. The experiment used the inactivated new coronavirus vaccine (Sinovac) to immunize mice, and 6-week-old WT C57BL / 6J female mice were randomly divided into two groups, the vaccine alone group (Sinovac) and the TCS mixed vaccine group (TCS / Sinovac), with 5 mice in each group. The specific operation is as follows: TCS / Sinovac group: 20μg / ml TCS is prepared, and 50μl and 50μl Sinovac are taken to immunize mice through the footpad in a total volume of 100μl; Sinovac group: 50μl phosphate solution for injection and 50μl Sinovac are taken to immunize mice through the footpad in a total volume of 100μl. After the initial immunization, booster immunization is performed every three weeks. One week after each immunization, blood is collected from the mouse retinal venous plexus, and serum is retained for ELISA testing. The TCS solution used in the experiment was prepared from the trichosanthes protein powder extracted and purified from the traditional Chinese medicine trichosanthes. The trichosanthes protein powder comes from the dried roots of Trichosanthes kirilowii Maxim, a plant of the Trichosanthes family. TCS was prepared using a phosphate solution for injection. ELISA tests showed that the level of RBD-specific IgG antibodies in mouse serum was significantly increased, and the high level of antibody titers could be maintained until the 13th week. At 13 weeks after the primary immunization, the spleens of mice were taken and the level of pan-B cell TLR7 mRNA in the spleen was detected. It was found that the level of TLR7 mRNA in B cells of mice in the experimental group was significantly increased compared with that in the control group ( Figure 4 ).

[0028] In vitro experiments showed that TCS can significantly promote the proliferation of germinal center B cells and plasma cells through the TLR7 signaling pathway. Pan-B cells in the spleen of WT female mice were isolated in vitro, and the cell ratio was detected by flow cytometry after adding different concentrations of TCS. The proportion of germinal center B cells and plasma cells increased significantly, especially when 0.5μg / ml TCS was added. This change disappeared after the addition of TLR7 inhibitor IRS661, suggesting that TCS exerts immune enhancement function through TLR7 ( Figure 5 ).

[0029] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and modifications without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of trichosanthin in the preparation of TLR7 agonists, It is characterized in that The application is suitable for enhancing TLR7 in preventive and therapeutic vaccines.

2. Application of trichosanthin in the preparation of new coronavirus vaccine immune adjuvant.

3. The use of trichosanthin according to claim 2 in the preparation of a novel coronavirus vaccine immune adjuvant, It is characterized in that The new coronavirus vaccines include oral vaccines, intravenous vaccines, arterial vaccines, mucosal vaccines, intramuscular vaccines, subcutaneous vaccines, organ injection vaccines or intrathoracic and intraperitoneal vaccines.

4. The use of trichosanthin according to claim 2 in the preparation of a novel coronavirus vaccine immune adjuvant, It is characterized in that The new coronavirus vaccines include the inactivated new coronavirus vaccine CoronaVac and the inactivated new coronavirus vaccine (Vero cell).